LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 93

Search options

  1. Book ; Thesis: Untersuchung zu Einflussfaktoren auf die Influenza-Impfraten bei COPD-Patienten

    Fischer, Bettina Corinna / Kaasch, Achim / Greulich, Timm

    2019  

    Title variant chronisch obstruktive Lungenerkrankung
    Institution Otto-von-Guericke-Universität Magdeburg
    Author's details Vorgelegt von Bettina Corinna Fischer aus Hamburg ; Gutachter: Achim Kaasch ; Timm Greulich
    Keywords Obstruktive Ventilationsstörung ; Impfung ; Grippe
    Subject Influenza ; Impfen ; Schutzimpfung ; Vakzination ; Aktive Immunisierung ; Vaccination ; Vakzinierung ; Obstruktive Atemwegserkrankung ; Chronic obstructive airway disease ; COAD ; Chronic obstructive pulmonary disease ; COPD ; Chronic obstructive lung disease ; COLD ; Chronisch obstruktive Lungenkrankheit
    Language German
    Size 4 ungezählte Blätter, 80 Blätter, Diagramme, Formulare
    Publisher Otto-von-Guericke-Universität Magdeburg
    Publishing place Magdeburg
    Publishing country Germany
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Dissertation, Universität Magdeburg, 2020
    HBZ-ID HT020645851
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2020 E 1576 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies.

    Greulich, Timm

    COPD

    2017  Volume 14, Issue sup1, Page(s) S8–S11

    Abstract: Alpha-1-antitrypsin deficiency (AATD) is one of the most frequent genetic causes of liver and lung diseases. Despite its known association with chronic obstructive pulmonary disease (COPD), AATD is largely unrecognised and underdiagnosed. Cases of AATD ... ...

    Abstract Alpha-1-antitrypsin deficiency (AATD) is one of the most frequent genetic causes of liver and lung diseases. Despite its known association with chronic obstructive pulmonary disease (COPD), AATD is largely unrecognised and underdiagnosed. Cases of AATD exist within every COPD or spirometry population but must be actively investigated. AATD is a laboratory diagnosis that must be confirmed by a blood test. A number of clinical 'clues' can raise suspicion of AATD, potentially facilitating earlier diagnosis and initiation of appropriate treatment. Alpha-1-antitrypsin augmentation therapy has a clear role in patients with severe AATD and a FEV
    Language English
    Publishing date 2017-03-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 2171107-0
    ISSN 1541-2563 ; 1541-2555
    ISSN (online) 1541-2563
    ISSN 1541-2555
    DOI 10.1080/15412555.2017.1286166
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5990: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Reply to correspondence "Extracellular vesicle microRNA signatures as novel biomarkers in obese asthmatics".

    Alhamdan, Fahd / Potaczek, Daniel P / Greulich, Timm / Tost, Jörg / Garn, Holger

    Allergy

    2024  Volume 79, Issue 5, Page(s) 1401–1402

    MeSH term(s) Humans ; MicroRNAs/genetics ; Extracellular Vesicles/metabolism ; Asthma/diagnosis ; Asthma/genetics ; Biomarkers ; Obesity/complications
    Chemical Substances MicroRNAs ; Biomarkers
    Language English
    Publishing date 2024-01-29
    Publishing country Denmark
    Document type Letter
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.16042
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.150: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 125: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book ; Online ; Thesis: High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients – a retrospective analysis

    Tüffers, Julia [Verfasser] / Greulich, Timm [Akademischer Betreuer]

    2023  

    Author's details Julia Tüffers ; Betreuer: Timm Greulich
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language English
    Publisher Philipps-Universität Marburg
    Publishing place Marburg
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Blood eosinophils as a marker of eosinophilic exacerbations in COPD.

    Greulich, Timm / Vogelmeier, Claus Franz

    The Lancet. Respiratory medicine

    2018  Volume 6, Issue 5, Page(s) e17

    MeSH term(s) Biomarkers ; Eosinophils ; Forced Expiratory Volume ; Humans ; Leukocyte Count ; Pulmonary Disease, Chronic Obstructive ; Sputum
    Chemical Substances Biomarkers
    Language English
    Publishing date 2018
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2686754-0
    ISSN 2213-2619 ; 2213-2600
    ISSN (online) 2213-2619
    ISSN 2213-2600
    DOI 10.1016/S2213-2600(18)30095-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7041: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Identification of extracellular vesicle microRNA signatures specifically linked to inflammatory and metabolic mechanisms in obesity‐associated low type‐2 asthma

    Alhamdan, Fahd / Greulich, Timm / Daviaud, Christian / Marsh, Leigh M. / Pedersen, Frauke / Thölken, Clemens / Pfefferle, Petra Ina / Bahmer, Thomas / Potaczek, Daniel P. / Tost, Jörg / Garn, Holger

    Allergy. 2023 Nov., v. 78, no. 11, p. 2944-2958

    2023  , Page(s) 2944–2958

    Abstract: RATIONALE AND OBJECTIVE: Plasma extracellular vesicles (EVs) represent a vital source of molecular information about health and disease states. Due to their heterogenous cellular sources, EVs and their cargo may predict specific pathomechanisms behind ... ...

    Abstract RATIONALE AND OBJECTIVE: Plasma extracellular vesicles (EVs) represent a vital source of molecular information about health and disease states. Due to their heterogenous cellular sources, EVs and their cargo may predict specific pathomechanisms behind disease phenotypes. Here we aimed to utilize EV microRNA (miRNA) signatures to gain new insights into underlying molecular mechanisms of obesity‐associated low type‐2 asthma. METHODS: Obese low type‐2 asthma (OA) and non‐obese low type‐2 asthma (NOA) patients were selected from an asthma cohort conjointly with healthy controls. Plasma EVs were isolated and characterised by nanoparticle tracking analysis. EV‐associated small RNAs were extracted, sequenced and bioinformatically analysed. RESULTS: Based on EV miRNA expression profiles, a clear distinction between the three study groups could be established using a principal component analysis. Integrative pathway analysis of potential target genes of the differentially expressed miRNAs revealed inflammatory cytokines (e.g., interleukin‐6, transforming growth factor‐beta, interferons) and metabolic factors (e.g., insulin, leptin) signalling pathways to be specifically associated with OA. The miR‐17–92 and miR‐106a–363 clusters were significantly enriched only in OA. These miRNA clusters exhibited discrete bivariate correlations with several key laboratory (e.g., C‐reactive protein) and lung function parameters. Plasma EV miRNA signatures mirrored blood‐derived CD4⁺ T‐cell transcriptome data, but achieved an even higher sensitivity in identifying specifically affected biological pathways. CONCLUSION: The identified plasma EV miRNA signatures and particularly the miR‐17–92 and ‐106a–363 clusters were capable to disentangle specific mechanisms of the obesity‐associated low type‐2 asthma phenotype, which may serve as basis for stratified treatment development.
    Keywords C-reactive protein ; T-lymphocytes ; asthma ; insulin ; interleukin-6 ; leptin ; lung function ; microRNA ; nanoparticles ; phenotype ; principal component analysis ; transcriptome
    Language English
    Dates of publication 2023-11
    Size p. 2944-2958
    Publishing place John Wiley & Sons, Ltd
    Document type Article ; Online
    Note JOURNAL ARTICLE
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.15824
    Database NAL-Catalogue (AGRICOLA)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.150: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 125: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Stufentherapie der COPD.

    Watz, Henrik / Kirsten, Anne / Greulich, Timm

    Deutsche medizinische Wochenschrift (1946)

    2019  Volume 144, Issue 1, Page(s) 15–20

    Abstract: The goal of pharmacologic therapy of stable chronic obstructive pulmonary disease (COPD) is to reduce symptoms, improve exercise intolerance and health-related quality of life, and to reduce exacerbations. Inhaled long-acting β2-agonists (LABAs) and long- ...

    Title translation The stepwise approach of COPD therapy.
    Abstract The goal of pharmacologic therapy of stable chronic obstructive pulmonary disease (COPD) is to reduce symptoms, improve exercise intolerance and health-related quality of life, and to reduce exacerbations. Inhaled long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are equally effective for the symptomatic management of COPD. However, LAMAs are more effective than LABAs in the reduction of exacerbations. In patients with symptomatic COPD pharmacologic therapy is usually escalated using the fixed combination of LAMAs and LABAs (dual bronchodilation), which is also superior to LAMA monotherapy in the prevention of exacerbations. Adding inhaled corticosteroids (ICS) to LABA and LAMA (triple therapy) for a prevention of exacerbations results in a further reduction of exacerbations, especially in those patients with higher blood eosinophil counts. Non-pharmacologic management of COPD patients includes smoking cessation programs, vaccination, pulmonary rehabilitation, and strategies to improve or maintain their physical activity.
    MeSH term(s) Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Adrenergic beta-2 Receptor Agonists ; Bronchodilator Agents/therapeutic use ; Humans ; Muscarinic Antagonists/therapeutic use ; Pulmonary Disease, Chronic Obstructive/drug therapy
    Chemical Substances Adrenal Cortex Hormones ; Adrenergic beta-2 Receptor Agonists ; Bronchodilator Agents ; Muscarinic Antagonists
    Language German
    Publishing date 2019-01-02
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-0570-3595
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Ua VI Zs.60/X: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients.

    Bertrams, Wilhelm / Wilhelm, Jochen / Veeger, Pia-Marie / Hanko, Carolina / Brinke, Kristina Auf dem / Klabunde, Björn / Pott, Hendrik / Weckler, Barbara / Greulich, Timm / Vogelmeier, Claus F / Schmeck, Bernd

    Frontiers in medicine

    2024  Volume 11, Page(s) 1234068

    Abstract: Introduction: Patients suffering from chronic obstructive pulmonary disease (COPD) are prone to acute exacerbations (AECOPD) or community acquired pneumonia (CAP), both posing severe risk of morbidity and mortality. There is no available biomarker that ... ...

    Abstract Introduction: Patients suffering from chronic obstructive pulmonary disease (COPD) are prone to acute exacerbations (AECOPD) or community acquired pneumonia (CAP), both posing severe risk of morbidity and mortality. There is no available biomarker that correctly separates AECOPD from COPD. However, because CAP and AECOPD differ in aetiology, treatment and prognosis, their discrimination would be important.
    Methods: This study analysed the ability of selected candidate transcripts from peripheral blood mononuclear cells (PBMCs) to differentiate between patients with AECOPD, COPD & CAP, and CAP without pre-existing COPD.
    Results: In a previous study, we identified differentially regulated genes between CAP and AECOPD in PBMCs. In the present new cohort, we tested the potential of selected candidate PBMC transcripts to differentiate at early time points AECOPD, CAP+COPD, and CAP without pre-existing COPD. Expression of
    Discussion: In summary, in our cohort expression levels of YWHAG,
    Language English
    Publishing date 2024-03-22
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2024.1234068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic.

    Herth, Felix J F / Sandhaus, Robert A / Turner, Alice M / Sucena, Maria / Welte, Tobias / Greulich, Timm

    International journal of chronic obstructive pulmonary disease

    2021  Volume 16, Page(s) 2983–2996

    Abstract: Alpha 1 Antitrypsin deficiency (AATD) is a hereditary condition characterized by low serum Alpha 1 Antitrypsin (AAT) levels and a predisposition towards early-onset emphysema. Infusion of AAT is the only disease-modifying therapy that can sufficiently ... ...

    Abstract Alpha 1 Antitrypsin deficiency (AATD) is a hereditary condition characterized by low serum Alpha 1 Antitrypsin (AAT) levels and a predisposition towards early-onset emphysema. Infusion of AAT is the only disease-modifying therapy that can sufficiently raise plasma AAT levels above the putative protective threshold and reduce the decline in lung density loss. Several randomized controlled trials (RCTs) and registry studies support the clinical efficacy of AAT therapy in slowing the progression of AATD-related emphysema and improving survival outcomes. The COVID-19 pandemic has prompted physicians to develop additional strategies for delivering AAT therapy, which are not only more convenient for the patient, but are "COVID-19 friendly", thereby reducing the risk of exposing these vulnerable patients. Intravenous (IV) self-administration of AAT therapy is likely to be beneficial in certain subgroups of patients with AATD and can remove the need for weekly hospital visits, thereby improving independence and well-being. Increasing the awareness of self-administration in AATD through the development of formal guidelines and training programs is required among both physicians and patients and will play an essential role, especially post-COVID-19, in encouraging physicians to consider self-administration for AATD in suitable patients. This review summarizes the benefits of AAT therapy on the clinical endpoints of mortality and quality of life (QoL) and discusses the benefits of self-administration therapy compared with conventional therapy administered by a healthcare professional. In addition, this review highlights the challenges of providing AAT therapy during the COVID-19 pandemic and the potential considerations for its implementation thereafter.
    MeSH term(s) COVID-19 ; Humans ; Pandemics ; Pulmonary Disease, Chronic Obstructive ; Registries ; SARS-CoV-2 ; alpha 1-Antitrypsin ; alpha 1-Antitrypsin Deficiency/diagnosis ; alpha 1-Antitrypsin Deficiency/drug therapy ; alpha 1-Antitrypsin Deficiency/epidemiology
    Chemical Substances alpha 1-Antitrypsin
    Language English
    Publishing date 2021-11-01
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2212419-6
    ISSN 1178-2005 ; 1176-9106
    ISSN (online) 1178-2005
    ISSN 1176-9106
    DOI 10.2147/COPD.S325211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis.

    Greulich, Timm / Vogelmeier, Claus F

    Therapeutic advances in respiratory disease

    2015  Volume 10, Issue 1, Page(s) 72–84

    Abstract: Alpha-1-antitrypsin deficiency (AATD) is a hereditary disorder that is characterized by a low serum level of alpha-1-antitrypsin (AAT). The loss of anti-inflammatory and antiproteolytic functions, together with pro-inflammatory effects of polymerized AAT ...

    Abstract Alpha-1-antitrypsin deficiency (AATD) is a hereditary disorder that is characterized by a low serum level of alpha-1-antitrypsin (AAT). The loss of anti-inflammatory and antiproteolytic functions, together with pro-inflammatory effects of polymerized AAT contribute to protein degradation and increased inflammation resulting in an increased risk of developing chronic obstructive pulmonary disease (COPD) and emphysema, especially in smokers. AATD is a rare disease that is significantly underdiagnosed. According to recent data that are based on extrapolations, in many countries only 5-15% of homozygous individuals have been identified. Furthermore, the diagnostic delay typically exceeds 5 years, resulting in an average age at diagnosis of about 45 years. Although the American Thoracic Society/European Respiratory Society recommendations state that all symptomatic adults with persistent airway obstruction should be screened, these recommendations are not being followed. Potential reasons for that include missing knowledge about the disease and the appropriate tests, and the low awareness of physicians with regard to the disorder. Once the decision to initiate testing has been made, a screening test (AAT serum level or other) should be performed. Further diagnostic evaluation is based on the following techniques: polymerase chain reaction (PCR) for frequent and clinically important mutations, isoelectric focusing (IEF) with or without immunoblotting, and sequencing of the gene locus coding for AAT. Various diagnostic algorithms have been published for AATD detection (severe deficiency or carrier status). Modern laboratory approaches like the use of serum separator cards, a lateral flow assay to detect the Z-protein, and a broader availability of next-generation sequencing are recent advances, likely to alter existing algorithms.
    MeSH term(s) Adult ; Delayed Diagnosis ; Humans ; Isoelectric Focusing ; Mass Screening/methods ; Middle Aged ; Polymerase Chain Reaction ; Pulmonary Disease, Chronic Obstructive/etiology ; Pulmonary Emphysema/etiology ; Smoking/adverse effects ; alpha 1-Antitrypsin/blood ; alpha 1-Antitrypsin Deficiency/diagnosis ; alpha 1-Antitrypsin Deficiency/genetics ; alpha 1-Antitrypsin Deficiency/physiopathology
    Chemical Substances alpha 1-Antitrypsin
    Language English
    Publishing date 2015-09-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2476459-0
    ISSN 1753-4666 ; 1753-4658
    ISSN (online) 1753-4666
    ISSN 1753-4658
    DOI 10.1177/1753465815602162
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6753: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top